General aspects of diabetes mellitus

Uazman Alam, Omar Asghar, Shazli Azmi, Rayaz Malik

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Diabetes mellitus is a heterogeneous group of disorders characterized by hyperglycemia due to an absolute or relative deficit in insulin production or action. The chronic hyperglycemia of diabetes mellitus is associated with end organ damage, dysfunction, and failure, including the retina, kidney, nervous system, heart, and blood vessels. The International Diabetes Federation (IDF) estimated an overall prevalence of diabetes mellitus to be 366 million in 2011, and predicted a rise to 552 million by 2030. The treatment of diabetes mellitus is determined by the etiopathology and is most commonly subdivided in type 1 and type 2 diabetes mellitus. There is a greater propensity towards hyperglycemia in individuals with coexisting genetic predisposition or concomitant drug therapy such as corticosteroids. The screening for diabetes mellitus may either be in the form of a 2. hour oral glucose tolerance test, or via HbA1c testing, as recently recommended by the American Diabetes Association (ADA). Strong associations have been shown in observational studies suggesting poor clinical outcomes both with chronic hyperglycemia and acutely in intensive care settings. However, tight glycemic control in this setting is a contentious issue with an increased incidence of hypoglycemia and possible increase in morbidity and mortality. In a critically ill patient a glucose range of 140-180. mg/dL (7.8-10.0. mmol/L) should be maintained via continuous intravenous insulin infusion.

Original languageEnglish
Pages (from-to)211-222
Number of pages12
JournalHandbook of Clinical Neurology
Volume126
DOIs
Publication statusPublished - 2014

Fingerprint

Diabetes Mellitus
Hyperglycemia
Insulin
Critical Care
Genetic Predisposition to Disease
Glucose Tolerance Test
Type 1 Diabetes Mellitus
Hypoglycemia
Intravenous Infusions
Critical Illness
Type 2 Diabetes Mellitus
Nervous System
Observational Studies
Blood Vessels
Retina
Adrenal Cortex Hormones
Morbidity
Kidney
Glucose
Drug Therapy

Keywords

  • Diabetes mellitus
  • Inpatient glycemic control
  • MODY
  • Type 1 diabetes mellitus
  • Type 2 diabetes mellitus
  • Variable rate insulin infusion

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

General aspects of diabetes mellitus. / Alam, Uazman; Asghar, Omar; Azmi, Shazli; Malik, Rayaz.

In: Handbook of Clinical Neurology, Vol. 126, 2014, p. 211-222.

Research output: Contribution to journalArticle

Alam, Uazman ; Asghar, Omar ; Azmi, Shazli ; Malik, Rayaz. / General aspects of diabetes mellitus. In: Handbook of Clinical Neurology. 2014 ; Vol. 126. pp. 211-222.
@article{c9350a6dc05942829353161d77ad56a4,
title = "General aspects of diabetes mellitus",
abstract = "Diabetes mellitus is a heterogeneous group of disorders characterized by hyperglycemia due to an absolute or relative deficit in insulin production or action. The chronic hyperglycemia of diabetes mellitus is associated with end organ damage, dysfunction, and failure, including the retina, kidney, nervous system, heart, and blood vessels. The International Diabetes Federation (IDF) estimated an overall prevalence of diabetes mellitus to be 366 million in 2011, and predicted a rise to 552 million by 2030. The treatment of diabetes mellitus is determined by the etiopathology and is most commonly subdivided in type 1 and type 2 diabetes mellitus. There is a greater propensity towards hyperglycemia in individuals with coexisting genetic predisposition or concomitant drug therapy such as corticosteroids. The screening for diabetes mellitus may either be in the form of a 2. hour oral glucose tolerance test, or via HbA1c testing, as recently recommended by the American Diabetes Association (ADA). Strong associations have been shown in observational studies suggesting poor clinical outcomes both with chronic hyperglycemia and acutely in intensive care settings. However, tight glycemic control in this setting is a contentious issue with an increased incidence of hypoglycemia and possible increase in morbidity and mortality. In a critically ill patient a glucose range of 140-180. mg/dL (7.8-10.0. mmol/L) should be maintained via continuous intravenous insulin infusion.",
keywords = "Diabetes mellitus, Inpatient glycemic control, MODY, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Variable rate insulin infusion",
author = "Uazman Alam and Omar Asghar and Shazli Azmi and Rayaz Malik",
year = "2014",
doi = "10.1016/B978-0-444-53480-4.00015-1",
language = "English",
volume = "126",
pages = "211--222",
journal = "Handbook of Clinical Neurology",
issn = "0072-9752",
publisher = "Elsevier",

}

TY - JOUR

T1 - General aspects of diabetes mellitus

AU - Alam, Uazman

AU - Asghar, Omar

AU - Azmi, Shazli

AU - Malik, Rayaz

PY - 2014

Y1 - 2014

N2 - Diabetes mellitus is a heterogeneous group of disorders characterized by hyperglycemia due to an absolute or relative deficit in insulin production or action. The chronic hyperglycemia of diabetes mellitus is associated with end organ damage, dysfunction, and failure, including the retina, kidney, nervous system, heart, and blood vessels. The International Diabetes Federation (IDF) estimated an overall prevalence of diabetes mellitus to be 366 million in 2011, and predicted a rise to 552 million by 2030. The treatment of diabetes mellitus is determined by the etiopathology and is most commonly subdivided in type 1 and type 2 diabetes mellitus. There is a greater propensity towards hyperglycemia in individuals with coexisting genetic predisposition or concomitant drug therapy such as corticosteroids. The screening for diabetes mellitus may either be in the form of a 2. hour oral glucose tolerance test, or via HbA1c testing, as recently recommended by the American Diabetes Association (ADA). Strong associations have been shown in observational studies suggesting poor clinical outcomes both with chronic hyperglycemia and acutely in intensive care settings. However, tight glycemic control in this setting is a contentious issue with an increased incidence of hypoglycemia and possible increase in morbidity and mortality. In a critically ill patient a glucose range of 140-180. mg/dL (7.8-10.0. mmol/L) should be maintained via continuous intravenous insulin infusion.

AB - Diabetes mellitus is a heterogeneous group of disorders characterized by hyperglycemia due to an absolute or relative deficit in insulin production or action. The chronic hyperglycemia of diabetes mellitus is associated with end organ damage, dysfunction, and failure, including the retina, kidney, nervous system, heart, and blood vessels. The International Diabetes Federation (IDF) estimated an overall prevalence of diabetes mellitus to be 366 million in 2011, and predicted a rise to 552 million by 2030. The treatment of diabetes mellitus is determined by the etiopathology and is most commonly subdivided in type 1 and type 2 diabetes mellitus. There is a greater propensity towards hyperglycemia in individuals with coexisting genetic predisposition or concomitant drug therapy such as corticosteroids. The screening for diabetes mellitus may either be in the form of a 2. hour oral glucose tolerance test, or via HbA1c testing, as recently recommended by the American Diabetes Association (ADA). Strong associations have been shown in observational studies suggesting poor clinical outcomes both with chronic hyperglycemia and acutely in intensive care settings. However, tight glycemic control in this setting is a contentious issue with an increased incidence of hypoglycemia and possible increase in morbidity and mortality. In a critically ill patient a glucose range of 140-180. mg/dL (7.8-10.0. mmol/L) should be maintained via continuous intravenous insulin infusion.

KW - Diabetes mellitus

KW - Inpatient glycemic control

KW - MODY

KW - Type 1 diabetes mellitus

KW - Type 2 diabetes mellitus

KW - Variable rate insulin infusion

UR - http://www.scopus.com/inward/record.url?scp=84921988214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921988214&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-53480-4.00015-1

DO - 10.1016/B978-0-444-53480-4.00015-1

M3 - Article

VL - 126

SP - 211

EP - 222

JO - Handbook of Clinical Neurology

JF - Handbook of Clinical Neurology

SN - 0072-9752

ER -